Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Advances in covalent drug discovery
Lydia Boike, Nathaniel J. Henning, Daniel K. Nomura
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 12, pp. 881-898
Open Access | Times Cited: 469

Showing 51-75 of 469 citing articles:

Target Discovery Driven by Chemical Biology and Computational Biology
B J Lyu, Wenfeng Gou, Feifei Xu, et al.
The Chemical Record (2025)
Closed Access | Times Cited: 1
First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer
Ramona Rudalska, Jule Harbig, Michael Förster, et al.
Nature Cancer (2025)
Open Access | Times Cited: 1
Access to N-α-deuterated amino acids and DNA conjugates via Ca(II)-HFIP-mediated reductive deutero-amination of α-oxo-carbonyl compounds
Haoran Li, Yuwei Liu, Silin Zhang, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
James Cregg, Kristóf Póta, Aidan C.A. Tomlinson, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 1
Antibiotic target discovery by integrated phenotypic and activity-based profiling of electrophilic fragments
Yizhen Jin, Sadhan Jana, Mikail E. Abbasov, et al.
Cell chemical biology (2025)
Open Access | Times Cited: 1
Morita–Baylis–Hillman Adduct Chemistry as a Tool for the Design of Lysine-Targeted Covalent Ligands
Marco Paolino, Giusy Tassone, Paolo Governa, et al.
ACS Medicinal Chemistry Letters (2025) Vol. 16, Iss. 3, pp. 397-405
Closed Access | Times Cited: 1
Viral proteases as therapeutic targets
Taťána Majerová, Jan Konvalinka
Molecular Aspects of Medicine (2022) Vol. 88, pp. 101159-101159
Open Access | Times Cited: 34
Peptide‐based covalent inhibitors of protein–protein interactions
Felix M. Paulussen, Tom N. Grossmann
Journal of Peptide Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 30
How many kinases are druggable? A review of our current understanding
Brian Anderson, Peter Rosston, Han Wee Ong, et al.
Biochemical Journal (2023) Vol. 480, Iss. 16, pp. 1331-1363
Open Access | Times Cited: 21
Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence
Miquel Duran‐Frigola, Marko Cigler, Georg E. Winter
Journal of the American Chemical Society (2023) Vol. 145, Iss. 5, pp. 2711-2732
Open Access | Times Cited: 20
The expanding repertoire of covalent warheads for drug discovery
Namrashee V. Mehta, Mariam S. Degani
Drug Discovery Today (2023) Vol. 28, Iss. 12, pp. 103799-103799
Closed Access | Times Cited: 20
Chemical technology principles for selective bioconjugation of proteins and antibodies
Preeti Chauhan, V. Ragendu, Mohan Kumar, et al.
Chemical Society Reviews (2023) Vol. 53, Iss. 1, pp. 380-449
Closed Access | Times Cited: 19
Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors
Lala S. Rathod, Pratap S. Dabhade, Santosh N. Mokale
Drug Discovery Today (2023) Vol. 28, Iss. 5, pp. 103557-103557
Closed Access | Times Cited: 18
Identification of Covalent Cyclic Peptide Inhibitors in mRNA Display
Sabrina E. Iskandar, Lilly Chiou, Thomas Leisner, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 28, pp. 15065-15070
Open Access | Times Cited: 18
Proteome‐Wide Fragment‐Based Ligand and Target Discovery
Ines Forrest, Christopher G. Parker
Israel Journal of Chemistry (2023) Vol. 63, Iss. 3-4
Open Access | Times Cited: 16
Biomimetic Synthesis and Chemical Proteomics Reveal the Mechanism of Action and Functional Targets of Phloroglucinol Meroterpenoids
Amy K. Bracken, Colby E. Gekko, Nina O. Suss, et al.
Journal of the American Chemical Society (2024) Vol. 146, Iss. 4, pp. 2524-2548
Open Access | Times Cited: 7
Peptide-Based Covalent Inhibitors Bearing Mild Electrophiles to Target a Conserved His Residue of the Bacterial Sliding Clamp
Guillaume Compain, Clément Monsarrat, Julie Blagojevic, et al.
JACS Au (2024) Vol. 4, Iss. 2, pp. 432-440
Open Access | Times Cited: 7
Oridonin inhibits bladder cancer survival and immune escape by covalently targeting HK1
Shuangjie Liu, Xialu Wang, Xiaojie Sun, et al.
Phytomedicine (2024) Vol. 126, pp. 155426-155426
Closed Access | Times Cited: 7
Electrophilic Compounds in the Human Diet and Their Role in the Induction of the Transcription Factor NRF2
Celia María Curieses Andrés, José Manuel Pérez de la Lastra, Elena Bustamante Munguira, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3521-3521
Open Access | Times Cited: 7
Discovery of a cell-active chikungunya virus nsP2 protease inhibitor using a covalent fragment-based screening approach
Eric M. Merten, John D. Sears, Tina M. Leisner, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 7
Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders
Corentin Bouvier, Rachel Lawrence, Francesca Cavallo, et al.
Cells (2024) Vol. 13, Iss. 7, pp. 578-578
Open Access | Times Cited: 7
The interplay between autophagy and cGAS-STING signaling and its implications for cancer
Maximilian Schmid, Patrick D. Fischer, Magdalena Engl, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Molecular glues and induced proximity: An evolution of tools and discovery
Stephanie Anne Robinson, J Co, Steven M. Banik
Cell chemical biology (2024) Vol. 31, Iss. 6, pp. 1089-1100
Closed Access | Times Cited: 7
Know your molecule: pharmacological characterization of drug candidates to enhance efficacy and reduce late-stage attrition
Terry Kenakin
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 8, pp. 626-644
Closed Access | Times Cited: 7
Identification of a cell-active chikungunya virus nsP2 protease inhibitor using a covalent fragment-based screening approach
Eric M. Merten, John D. Sears, Tina M. Leisner, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 42
Closed Access | Times Cited: 7

Scroll to top